Cue Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cue Biopharma, Inc.
Deal Snapshot: Cue’s pipeline is heavy on oncology, but it partnered with Merck on autoimmune in 2017 and while that work has shifted to cancer, the Ono partnership puts the focus back on autoimmune disease.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
The US National Institutes of Health and the Biomedical Advanced Research and Development Authority are asking manufacturers to provide new COVID-19 diagnostic candidates for NIH’s Rapid Acceleration of Diagnostics (RADx) program.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.